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Over the last 30 years, concomitant with successful transnational disease control programs
across Latin America, Chagas disease has expanded from a neglected, endemic parasitic
infection of the rural poor to an urbanized chronic disease, and now a potentially emergent
global health problem. Trypanosoma cruzi infection has a highly variable clinical course,
ranging from complete absence of symptoms to severe and often fatal cardiovascular and/or
gastrointestinal manifestations. To date, few correlates of clinical disease progression have
been identified. Elucidating a putative role for T. cruzi strain diversity in Chagas disease
pathogenesis is complicated by the scarcity of parasites in clinical specimens and the
limitations of our contemporary genotyping techniques. This article systematically reviews the
historical literature, given our current understanding of parasite genetic diversity, to evaluate
the evidence for any association between T. cruzi genotype and chronic clinical outcome, risk
of congenital transmission or reactivation and orally transmitted outbreaks.
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Background
Chagas disease is the most important parasitic
infection in Latin America, affecting an esti-
mated 5–6 million individuals, with a further
70 million at risk [1]. The geographical range of
the etiological agent, Trypanosoma cruzi (Kinet-
oplastida: Trypanosomatidae), extends from
the southern USA to Argentinean Patagonia,
where it is transmitted by more than 100 species
of hematophagous triatomine bugs (Hemiptera:
Reduviidae: Triatominae) [2,3] to at least eight
orders of domestic, synanthropic and sylvatic
mammalian hosts [4]. Human disease occurs
when infected triatomine feces enter through
intact mucosa or abraded skin [5]. Oral
transmission is an important secondary infec-
tion route, responsible for regional microepi-
demics of acute Chagas disease in areas often
devoid of domestic triatomine species, for
example, the Amazon Basin [6]. In recent years,
a significant proportion of the infected popula-
tion has emigrated from rural areas, leading to
the urbanization of Chagas disease in endemic
countries as well as internationally [7]. Chagas
disease is now considered an emergent global
public health problem associated with congeni-
tal transmission [8], blood transfusions [9] and
organ transplantations [10].
Following T. cruzi exposure, human infec-
tion begins with an acute phase, lasting up to
3 months, during which circulating
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trypomastigotes can be visualized in peripheral blood films or
buffy coat smears. Most individuals are asymptomatic or present
with a non-specific, self-limiting febrile illness [8]. Mortality dur-
ing the acute phase is rare (<1% of cases) and may result from
severe myocarditis, pericardial effusion and/or meningoencepha-
litis [11]. Acute mortality occurs more frequently in infants and
immunocompromised patients than other infected persons. Even
in the absence of treatment, the acute phase spontaneously
resolves in most individuals [8,11].
Chronic infection is initially asymptomatic and the majority
of patients will remain clinically indeterminate for life. How-
ever, over a period of 10–30 years, approximately 20–30% of
infected individuals will develop irreversible, potentially fatal
cardiac syndromes (chronic chagasic cardiomyopathy [CCM])
and/or dilatation of the GI tract (megacolon or megaesopha-
gus) [11]. Early CCM is typically characterized by conduction
system abnormalities, particularly right bundle branch block
and/or left anterior fascicular block, and premature ventricular
contractions [12]. More advanced manifestations include ventric-
ular tachycardia, high-degree atrioventricular block and progres-
sive dilated cardiomyopathy with congestive heart failure [13].
Sudden death accounts for 30–65% of CCM-related mortality
and can affect patients with end-stage heart disease as well as
those who were previously asymptomatic [14]. Gastrointestinal
(GI) megasyndromes are rarer than cardiac sequelae, resulting
from denervation, decreased motility, sphincter dysfunction
and eventual luminal dilatation of the esophagus and/or
colon [15]. However, the prevalence of different clinical forms,
especially digestive disease, varies considerably between geo-
graphical regions [16,17].
Clinical staging of CCM
Multiple expert committees have published guidelines for the
standard evaluation of patients with chronic T. cruzi infec-
tion [18–20]. All recommend thorough history and physical
examination, and at a minimum, a 12-lead ECG. Some com-
mittees also recommend echocardiograms and/or barium stud-
ies of the esophagus and colon. If all of these are normal, the
patient is considered to have the indeterminate form of Chagas
disease (IND). The expert committee convened by the US
CDC advised that barium studies only be performed if the
patient reported GI symptoms, based on the low prevalence of
the digestive form of Chagas disease in Mexico and Central
America, the source of most infected individuals in the
USA [18]. This committee also recommended against perform-
ing echocardiograms on patients with no cardiac symptoms or
ECG abnormalities, because significant abnormal findings on
echocardiogram are rare in the absence of other indications of
Chagas cardiomyopathy.
Several systems have been used to characterize the severity of
CCM for clinical staging and epidemiological studies. The
most commonly cited schemes are the modified Kuschnir clas-
sification, the Los Andes classification and the more recent sys-
tem that incorporates the American College of Cardiology/
American Heart Association criteria for congestive heart failure
staging [21–24]. All use similar general criteria, including specific
ECG abnormalities plus chest radiography or echocardiogram
to provide measures of left ventricular size and/or ejection frac-
tion (see comparative table in [18]). However, many investiga-
tors add other modifications based on their own clinical
experience, to provide finer scale classification or increase the
specificity of staging [25,26]. Many ECG findings that are listed
in these schemes to define early CCM, such as low voltage and
right bundle branch block, occur in other cardiac diseases and
are fairly common in older age groups, independent of T. cruzi
infection status [27]. Others, such as moderate bradycardia and
incomplete right bundle branch block, are normal variants in
healthy young people [28]. While the most severe stage in any
of the common classification schemes (equivalent to advanced
congestive heart failure) is highly predictive of mortality [29],
there is no obvious method to verify the clinical or epidemio-
logical validity of criteria for the earlier stages. The use of het-
erogeneous classification schemes directly impedes comparisons
of epidemiological studies of CCM severity and prevalence,
and meta-analyses of the relationship between Chagas disease
pathogenesis and T. cruzi strain diversity.
A brief history of T. cruzi taxonomy
T. cruzi is an ancient parasite, estimated to have diverged from
its most recent common ancestor 3–4 million years ago [30],
and as such, displays considerable genetic diversity. Current
international consensus recognizes a minimum of six stable
genetic lineages: TcI–TcVI [31]. A potential seventh bat-
restricted genotype (TcBat), with genetic affiliations to TcI, has
recently been reported in Central and northern South Amer-
ica [32–34]. Historically, the taxonomy of T. cruzi has been hin-
dered by a lack of standardized molecular typing methods and
the use of various alternative nomenclatures (TABLE 1) [35].
The earliest attempts to characterize T. cruzi strain variation,
based on multilocus enzyme electrophoresis (MLEE), classified
isolates into three major groups or ‘zymodemes I, II and
III’ [36,37], which were later subdivided into 43 ‘clonets’ [38].
Subsequent genotyping of additional strains using MLEE [39],
random amplification of polymorphic DNA [40] and nuclear
loci [41–43] grouped isolates into two major lineages, designated
T. cruzi I and T. cruzi II [44]. More recently, supported by
MLEE and multilocus sequence typing, TcII was separated into
TcIIa–e [45,46], which were latterly renamed as TcII–TcVI to
remove any presumptive sublineage designations [31]. Each of
the six former T. cruzi genetic lineages is now considered a dis-
crete typing unit (DTU), defined as ‘a collection of strains that
are genetically more closely related to each other than to any
other strain and that share one or several specific characters’ [47].
However, the criteria for division, number of subgroups, and
their precise biological and evolutionary relevance are still a
popular subject of debate [48–57].
The principal reproductive mode of T. cruzi, in particular
the relative contributions of clonality and sexuality to parasite
population structures and the evolution of discrete DTUs, is
also contentious [58,59]. DTUs TcI–TcIV form monophyletic
Review Messenger, Miles & Bern









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































clades and TcV and TcVI are known to be recent inter-lineage
hybrids [30]. As such, TcI–TcIV are characterized by substantial
allelic homozygosity, likely resulting from recurrent, dispersed,
genome-wide gene conversion, while TcV and TcVI display
natural heterozygosity and minimal distinction, sharing intact
alleles from their parental progenitors (TcII and TcIII)
[54,57,60–62].
Molecular epidemiology of T. cruzi
Molecular epidemiology studies have made substantial progress
defining the phylogeographical and ecological niche of each
T. cruzi lineage (TABLE 2) [63]. Sylvatic DTU distribution data are
still largely aggregated due to differences in ease of capture
between reservoir species, paucity of supporting ecological
information and our inability to genotype subpatent zoonotic
infections [64].
In general, TcI, TcII, TcV and TcVI are most frequently
isolated from domestic cycles and responsible for the majority
of human infections. TcI has the widest distribution; it is the
principal cause of Chagas disease in Colombia and Vene-
zuela [65–67] and ubiquitous in the sylvatic environment [68,69],
primarily circulating in arboreal ecotopes between Didelphis
species and the triatomine tribe Rhodniini [70,71], with secondary
terrestrial transmission among rodents and sylvatic Triatoma
species in the inter-Andean valleys of Argentina, Bolivia, Peru
and Chile [72–77]. Multiple molecular markers consistently iden-
tify high levels of genetic diversity within sylvatic TcI popula-
tions [48–51,70,78], and divergent, but genetically homogeneous,
strains associated with domestic vectors and human
infections [52,53,70].
By comparison, TcII, TcV and TcVI are less genetically
diverse overall [30] and appear largely confined to domestic
transmission cycles in southern parts of South America [63].
The sylvatic reservoirs of these three DTUs are not fully
defined, although TcII has been increasingly isolated from pri-
mates in Brazil [64,79–81]; peridomestic dogs are emerging as
potential reservoirs of TcV and TcVI in the Gran Chaco
region [82–85]. The geographical range of TcV and VI appears
to be more extensive than previously suggested, with isolated
reports of these hybrid DTUs as far north as Ecuador [86] and
Colombia [87]. TcIII has a dispersed terrestrial distribution that
extends from northeastern Venezuela to Argentina, where it is
transmitted by Panstrongylus geniculatus to Dasypus novemcinctus
and other fossorial mammals [88–92]. TcIV is poorly under-
stood, principally because several genotyping methods fail to
distinguish this lineage from others, especially from
TcIII [42,93,94]. However, TcIV is known to circulate sympatri-
cally with TcI in wild primates, Monodelphis and Dasypus spp.
in the Amazon [95] and raccoons and dogs in North
America [96]. TcIV is also increasingly detected in human dis-
ease, as a secondary agent of Chagas disease in Venezuela [16,66],
and in recent oral outbreaks in the Brazilian Amazon [95,93,97–99].
As of now, TcIII and TcIV have only been sporadically
detected in domestic transmission cycles, but this may be
attributable to undersampling and the limited sensitivity of
some genotyping methods [100]. Finally, TcBat, a new, geneti-
cally divergent and potentially human-infective lineage [101],
has been isolated from Chiroptera species across Panama [33],
Brazil [32] and Colombia [34].
T. cruzi clinical genotyping: perils & pitfalls
Establishing an association between T. cruzi genotype and clini-
cal outcome is complicated by inherent biological features relat-
ing to parasite infection dynamics, as well as the limitations of
our current repertoire of genotyping techniques. In
humans [53,102–104], triatomine bugs [85,105,106] and mammalian
reservoir hosts [88,107,108], mixed infections of distinct parasite
clones are not exceptional but, in many cases, inevitable. In
highly endemic areas, long-term inhabitants are repeatedly
infected by multiple contacts with different triatomines [109],
which in turn may have fed on various infected humans and/or
mammals, depending on the local disease ecology.
Levels of intra-patient parasite multiclonality might be
expected to increase proportionally with vector exposure. How-
ever, this assumes a constant force of infection, incomplete
cross-genotypic immunity, and lack of genotype interaction
(e.g., genotype displacement, reciprocal inhibition, potentiation
or recombination) [110–114], transmission population bottlenecks
(as observed in related trypanosomes [115]) or any additional
mechanisms that might alter the establishment of secondary
infections. The complexity of natural multiclonal parasite pop-
ulations is largely unknown and our ability to detect them is
restricted by genetic marker resolution [107,116]. The study of
this phenomenon conventionally necessitates deriving biological
clones from live parasite populations (by micromanipula-
tion [117], limiting dilution [118], plating on semi-solid media [106]
or FACS [116]), prior to genetic typing, which introduces a
range of potential adaptation biases, discussed below.
Genotyping of T. cruzi can be performed either directly
from clinical samples (blood or tissue biopsies) or following
parasite isolation by hemoculture or xenodiagnosis. Due to the
scarcity of parasites in peripheral blood, especially in chroni-
cally infected patients, the former method has limited sensitiv-
ity. The primary drawback associated with parasite isolation is
selection bias for particular subpopulations, initially by prefer-
ential outgrowth due to faster dividing rates and/or culture
media [55,119,120] and subsequently by loss of clonal diversity
from serial maintenance in axenic culture or animals [121–126].
Hemoculturing is laborious; recovery rates are usually less than
30% among chronic patients [127] and almost entirely deter-
mined by parasite load and distribution within the starting
sample. Xenodiagnosis, which can facilitate greater parasite
recovery, has also been shown to vary depending on vector per-
missibility to local strains [128–130]. Furthermore, due to differ-
ential strain tropisms, circulating clones isolated by
hemoculture or xenodiagnosis are often genetically distinct
from those sequestered in tissues [102–104] and can vary even
between sequential blood samples [131]. Together, these observa-
tions strongly suggest that intra-host parasite diversity is rou-
tinely underestimated.
Review Messenger, Miles & Bern
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A plethora of molecular genotyping techniques have been
developed to characterize T. cruzi genetic diversity, with vary-
ing degrees of resolution, experimental ease, reproducibility,
subjectivity and transferability (TABLE 3). Typing of genetic poly-
morphisms in conserved housekeeping genes can define major
genetic lineages [41–43,45,46,61,132], while analysis of hypervariable
loci such as microsatellites [70,89,133,134], or kinetoplast DNA
(kDNA) minicircles [135–139] potentially allows identification of
profiles specific to individual strains. Choice of typing method-
ology is principally determined by sample source, research
objective and laboratory resources.
Direct clinical genotyping is currently based on size poly-
morphisms in multi-copy genetic markers, including the
nuclear spliced-leader intergenic region, 24a rDNA [41], 18S
rDNA [46], A10 [135] and kinetoplast hypervariable minicircle
sequences [136–139] (for more detailed descriptions of historical
genotyping techniques, see [55,140,141]). One major confounder
associated with the use of any multi-copy gene is the level of
intra-clone copy number and position homology to ensure
comparability between strains. Genome size [142,143], karyo-
type [144–148] and chromosomal arrangements of tandem repeat
regions [149,150] are known to differ widely between natural
T. cruzi strains and even biological clones derived from the
same population. Similar caveats affect minicircle-based geno-
typing, which vary in copy number and complement between
major DTUs [136,151], are susceptible to contamination [152] and
whose profiles are highly sensitive to minor changes in reaction
conditions, raising issues of reproducibility [121,153]. With many
of these methods, strain DTU assignment is dependent on
absence of PCR products/restriction fragment bands, which can
also result from novel variation in as yet untested strains; a typ-
ing methodology is only as ‘good’ as the panel of reference
strains used to validate it.
Additional genotyping options are available for axenic para-
site cultures, including karyotyping [154,155], DNA fingerprint-
ing [156] and microsatellite analyses [53,70,78,89,157]. To date, no
single, widely validated genetic marker affords complete,
unequivocal DTU resolution [158], and reliance on only one tar-
get is inadvisable given the potential confounding influence of
genetic exchange [57]. The availability of reference whole
genome sequences [159–162] has reinvigorated interest in explor-
ing the relevance of T. cruzi genetic diversity to clinical out-
comes of Chagas disease. However, comparative genomics of
representative T. cruzi field isolates is not yet a reality, as is the
case with other more experimentally tractable trypanosomatid
species [163–165].
Methods for the systematic literature review
To date, few correlates of chronic disease progression and
clinical manifestations have been identified, although both
host and parasite genetics are presumed to be
involved [140,166,167]. Herein, the authors systematically review
the literature, given our current understanding of T. cruzi
genetic diversity, to re-evaluate the evidence for any associa-
tion between parasite genotype and clinical outcome, risk of
congenital transmission or reactivation, and orally transmitted
outbreaks.
Independent queries of the literature were performed using
the electronic databases MEDLINE/PubMed, Web of Science
v5.15, EMBASE and Scopus, with no restrictions to language
or calendar date. To retrieve chronic patient studies, the follow-
ing search terms were used: ‘chronic’ or ‘patients’ AND
‘Chagas disease’ or ‘cruzi’ AND ‘DTU’ or ‘DTUs’ or ‘lineage’
or ‘lineages’ or ‘genotype’ or ‘genotypes’ or ‘genotyping’. To
retrieve congenital studies, the following search terms were
used: ‘congenital’ or ‘maternal’ or ‘neonate’ AND ‘Chagas dis-
ease’ or ‘cruzi’ AND ‘DTU’ or ‘DTUs’ or ‘lineage’ or ‘lineages’
or ‘genotype’ or ‘genotypes’ or ‘genotyping’. To retrieve reacti-
vation studies, the following search terms were used: ‘HIV’ or
‘transplant’ or ‘reactivation’ AND ‘Chagas disease’ or ‘cruzi’
AND ‘DTU’ or ‘DTUs’ or ‘lineage’ or ‘lineages’ or ‘genotype’
or ‘genotypes’ or ‘genotyping’. To retrieve oral transmission
studies, the following search terms were used: ‘oral’ or ‘acute’
AND ‘Chagas disease’ or ‘cruzi’ AND ‘DTU’ or ‘DTUs’ or
‘lineage’ or ‘lineages’ or ‘genotype’ or ‘genotypes’ or
‘genotyping’. In addition, reference lists from retrieved articles
were manually checked to identify further relevant studies.
For cohorts of chronic chagasic patients, original research
studies that met all of the following criteria were included: at a
minimum, patients were classified as ‘acute’, ‘indeterminate’
(i.e., asymptomatic) or ‘chronic’ (i.e., symptomatic) following
clinical examination; T. cruzi genotyping was performed on a
subset of infected patients, at least to DTU level; and results
were reported with reference to a recognizable T. cruzi nomen-
clature scheme, as detailed in TABLE 1.
For reactivation patients, original research studies that met
all of the following criteria were included: patients were clini-
cally classified as immunocompromised by confirmation of
HIV co-infection or following organ transplantation; T. cruzi
genotyping was performed on a subset of infected patients, at
least to DTU level; and results were reported with reference to
a recognizable T. cruzi nomenclature scheme (TABLE 1).
For congenital patients, original research studies that met all
of the following criteria were included: neonatal T. cruzi infec-
tion was established at birth, or shortly thereafter, but prior to
early childhood to be considered ‘congenitally infected’;
T. cruzi genotyping was performed on a subset of infected neo-
nates and/or mothers, at least to DTU level; and results were
reported with reference to a recognizable T. cruzi nomenclature
scheme (TABLE 1). An additional criterion (T. cruzi genotyping
performed on matched mother–infant samples) was dropped
when the initial literature search indicated that it would have
excluded all but three articles with a total of 23 mother–infant
pairs [135,168,169].
For oral outbreaks, original research studies that met all of
the following criteria were included: oral transmission was
confirmed on the basis of epidemiological indicators (e.g.,
familial clustering), incrimination of the contaminated food
source, clinical presentation (severe acute morbidity and/or
mortality) or exclusion of local vector-borne transmission;
Review Messenger, Miles & Bern









































































T. cruzi genotyping was performed on a subset of infected
patients, at least to DTU level; and results were reported
with reference to a recognizable T. cruzi nomenclature
scheme (TABLE 1).
Exclusion criteria included articles in languages other than
English or Spanish, unpublished reports (including dissertations
or conference abstracts), papers presenting solely animal data,
book chapters, prospective study protocols and review articles.
Patient case studies with sample size <5 were excluded from
the analysis of chronic chagasic patients. Because the literature
for congenital, reactivation and oral transmission is sparse by
comparison, we included all publications in these categories
that provided genotyping data from human-derived specimens
within a recognizable T. cruzi nomenclature scheme.
Chronic Chagas disease
The earliest evidence that chronic Chagas disease manifestations
may differ according to parasite strain came from reports of
geographical variation, in which the rarity of megasyndromes
in Venezuela compared to central and eastern Brazil was cir-
cumstantially linked to radical genetic differences between
T. cruzi zymodemes (TABLE 4) [16,17]. Based on the electrophoretic
mobilities of 6 [36] to 18 isoenzymes [170], ZI (TcI) was the
principal zymodeme identified in chronic patients (19/19) and
domestic (13/13) and sylvatic vectors and mammals (18/20) in
Venezuela. By comparison, in central and eastern Brazil, ZII
(TcII) was the most prevalent zymodeme in acute and chronic
patients (98/99) and domestic transmission cycles (9/9), but
not sylvatic reservoirs (ZI [TcI]: 23/25; ZIII [TcIV]: 2/25).
This dichotomy between principal parasite types was reinforced
by parallel observations from other regions of Bra-
zil [37,129,171,172]. In Belem, north Brazil, ZI (TcI) and ZIII
(TcIV) were incriminated in oral outbreaks and both were
found circulating among acute cases (3/7 and 4/7, respectively)
and the sylvatic environment (ZI [TcI]: 106/118; ZIII [TcIV]:
6/118; ZIII ASAT [TcIII]: 6/118) [16], while to the south-east,
ZII (TcII) was associated with chronic human Chagas disease
in Sa˜o Felipe, Bahia [37]. In neighboring parts of Goia´s, Bahia
and Minas Gerais, comparable proportions of ZI (TcI) and ZII
(TcII) were isolated from acute cases, with similar clinical
courses, but only ZII was identified in chronic patients present-
ing a range of cardiac and digestive symptoms [129,173].
Further south, most clinical reports supported the principal
involvement of Bolivian ZII (TcV) in chronic Chagas dis-
ease [174–176]. In northern Chile, the majority of patients,
regardless of symptom status, were infected with Bolivian ZII
(TcV) (64/85 and 101/116 CCM and IND patients, respec-
tively) [175,176]. However, one study in Bolivia detected TcI (clo-
net 7, 19 or 20) and TcV (clonet 39) in almost equal
proportions (17/27 and 10/27, respectively) from both IND
and symptomatic chronic individuals [174]. The latter study was
one of the first to describe a number of mixed infections (as
either a mixed isoenzyme profile or different isoenzyme profiles
from sequential parasite samples from an individual patient),
including three patients with TcI/TcV (clonets 7, 19 or 20 and
39) co-infections presenting both cardiac and digestive abnor-
malities [174]. Finally, in Argentina, stronger evidence of a link
between parasite genetics and progression to symptomatic dis-
ease was reported, with TcV prevailing in the IND form (30/
35 [86%]) and CCM significantly more associated with TcI
(10/14 [71%]) than TcV (7/37 [19%]) [177].
To date, these remain some of the largest cross-sectional
studies in which infecting T. cruzi genotype was directly exam-
ined in conjunction with patient clinical data (TABLE 4). Investiga-
tors noted that digestive Chagas disease was frequent in the
Southern Cone, coinciding with the absence of TcI and pre-
ponderance of TcII/V, and drew a contrast with the rarity of
digestive disease and predominance of TcI further north [16].
However, in these studies, very little genotypic data were
obtained for digestive patients (n = 16; 5 TcI, 8 TcII and
3 TcV) compared to those with CCM (n = 159; 38 TcI,
43 TcII and 78 TcV) or without symptomatic disease
(n = 217; 25 TcI, 30 TcII, 1 TcIV and 161 TcV) (TABLE 4). Fur-
thermore, some of the aforementioned experimental design and
biological limitations must be acknowledged alongside these
observations. In all of these early reports, MLEE was performed
using lysate prepared from parasites isolated through a combi-
nation of hemoculture, xendiagnosis and/or inoculation into
animals [129,173] and in each study, positive hemocultures were
obtained for less than one-third of patients (107/391 in
Chile [176] and 14/111 in Brazil [129]). Mixed infections were
identified by a handful of investigators who undertook biologi-
cal cloning of strains or sequential sampling [174,178], but were
not routinely investigated. At the time, research groups were
using separate MLEE protocols (although latterly determined
to be comparable [179]), different and varying standards of clini-
cal classification (some omitting any GI examination alto-
gether) [36,128,170,180,181], and finally confusing and conflicting
T. cruzi strain nomenclatures [1,16,42,43,129,177,174,176], hindering
any prospective meta-analysis across endemic regions.
With improved molecular techniques and the advent of
direct genotyping from clinical specimens, current evidence
suggests that parasite strains detected in peripheral blood from
patients with or without morbidity reflect the principal lineage
circulating in the local domestic cycle (TABLE 5). However, it
should also be noted that due to differential strain tropisms,
bloodstream parasites are not necessarily the same genotype
responsible for pathology [140]. In studies from northern Brazil,
Colombia, Guatemala, Mexico and Panama, TcI predominates
in both IND and CCM groups [182–187]; a minority of infec-
tions in Colombia were attributable to TcII (5/26 IND and 6/
41 CCM) [183,184]. The two largest recent endeavors to compare
T. cruzi genotypes in symptomatic versus asymptomatic Chagas
disease patients were conducted in Argentina (n = 172) [188]
and Bolivia (n = 132) [189] and support the association of
chronic infection, independent of symptom status, with TcII/
V/VI (149/149 IND, 98/98 CCM, 5/5 CCM-megacolon
(MC) and 40/44 MC). Despite the use of more sensitive
molecular genotyping techniques, results for approximately
30–50% of specimens were missing due to low parasite load in
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peripheral blood. Additional smaller studies also corroborate
these observations with domestic genotypes detected in both
patients’ blood [190,191] and cardiac, esophagus and colon tissue
specimens [192,193].
One recent method, developed to circumvent some of these
technical limitations, is to adopt an indirect approach, exploit-
ing serological detection of antibodies produced in response to
DTU-specific T. cruzi antigens, with the advantage of poten-
tially revealing both historical and contemporary infecting para-
site lineages. Consistent with genotypic data from the same
area, serosurveys in southern endemic regions using recombi-
nant peptides directed at trypomastigote small surface antigen
indicate pervasive infection with TcII/V/VI [194,195] and even a
putative association of ECG abnormalities with seroreactivity to
this particular protein [196].
Lastly, on a more cautionary note, three publications from
Chile report conflicting genotypic data from patients in longi-
tudinal follow-up after a clinical trial of allopurinol and
itraconazole (TABLE 5) [197–199]. In the first publication, using
kDNA Southern blots, more than 75% of the results in both
groups were described as ‘TcI + TcII + hybrid’ [197], perhaps
reflecting cross-reactivity between minicircle hybridization
probes [200]. Subsequent papers presenting nuclear microsatellite
genotyping from patients from the same clinical trial, with
unspecified degrees of overlap, demonstrated a predominance
of TcI (79% of 33 IND and 57% of 28 CCM in [198]; 86% of
28 IND and 71% of 24 CCM in [199]).
Chagas disease reactivation
Reactivation of Chagas disease may occur in infected individu-
als who become immunocompromised through immunosup-
pressive treatment (e.g., transplant recipients) or co-infection
with HIV [11,201]. Reactivation is characterized by increased par-
asite multiplication, a return to microscopically detectable para-
sitemia levels and symptoms more typical of acute T. cruzi
infection, including meningoencephalitis, acute myocarditis and
skin chagomas [201]. High parasite loads lead to more frequent
strain identification in immunocompromised than immuno-
competent patients [188]. In addition, the loss of immunological
control may allow parasites previously sequestered in deep tis-
sues to replicate and return to the circulation. Thus, patients
with reactivation arguably provide the best in vivo indicator of
the complexity of natural infections in humans [102–104].
Compared to results from immunocompetent individuals,
the detection of patent mixed infections is striking in some
immunocompromised patients, with multiple genotypes in a
single specimen or different genotypes in tissue compared to
blood (TABLE 6). TcI, hypothesized to have cardiac muscle tro-
pism, demonstrated contrasting distributions in tissue versus
blood in immunocompetent patients (38% in cardiac tissue vs
0% in blood) [188], but was detected at equal frequencies in tis-
sue and blood from cardiac transplant patients with reactivation
(31% in tissue vs 33% in blood) (TABLE 6) [188]. This result may
reflect unmasking of mixed infections that were below the level
of detection prior to reactivation.
Current data are insufficient to evaluate any association
between strain and clinical symptoms or risk of reactivation.
Analyses need to be designed to account for known risk factors
for reactivation (severity of immunocompromise and specific
immunosuppressive regimens) [201]. The most powerful design
is a longitudinal approach, for example, in end-stage CCM
patients evaluated for heart transplantation, combined with par-
asitological monitoring following surgery. However, pre- and
post-immunosuppression comparisons are difficult, given that
genotyping from blood of immunocompetent patients is lim-
ited by low peripheral parasitemia [104].
Congenital Chagas disease transmission
With improved vector control, congenital transmission has
become proportionately more important among chronically
infected populations, estimated to account for 22% of new
T. cruzi cases in 2015 [1]. Even if vector-borne transmission
were interrupted today, infected girls and women will continue
to transmit the infection to their children, sustaining the cycle
across generations in the absence of the vector [202].
Congenital T. cruzi infection is most often clinically silent,
but can cause a spectrum of presentations, including low birth
weight, prematurity and low Apgar scores to meningoencepha-
litis, hepatosplenomegaly, anemia, thrombocytopenia and respi-
ratory distress syndrome [203–205]. Higher morbidity and
mortality rates were described in the 1980s and 1990s com-
pared to more recent cohort data [204,206]. Clinically severe con-
genital infection is reported to be associated with higher levels
of neonatal parasitemia than less-severe or asymptomatic dis-
ease [207]. Congenital Chagas disease is also assumed to carry
the same risk of chronic cardiac and/or GI manifestations as
vector-borne infections.
Since the earliest descriptions of congenital T. cruzi infec-
tion [208–210], researchers have struggled to explain why vertical
transmission is restricted to only a small proportion of infected
mothers. Congenital transmission rates are highly variable both
within and between endemic areas, ranging from 4.4 to 11.3%
in Argentina [211–214], from 3.4 to 17.1% in Boli-
via [204,205,215,216], from 0.2 to 5.2% in Brazil [217,218], from
2.5 to 11.1% in Chile [219–221] and from 5.6 to 10% in Para-
guay [222,223]. Factors now known to be associated with higher
risk of congenital transmission include younger maternal age
(presumed to reflect more recent infection) [204], maternal and
neonatal immunological responses [224,225], higher maternal par-
asitemia [168,205,214], and HIV and other immunodeficien-
cies [226,227]; the evidence for any influence of T. cruzi genetic
diversity is more equivocal (TABLE 7). The majority of congenital
genotyping studies have been performed in southern endemic
areas, particularly Argentina, Bolivia and Chile, and in general,
mirror the distribution of TcII/V/VI lineages observed among
local chronic adult populations; additional studies are needed
from regions of domestic TcI transmission in northern South
and Central America [228,229].
A number of limitations prevent the accurate assessment of
the interaction between T. cruzi genotype and risk of
Review Messenger, Miles & Bern









































































congenital transmission. Studies which examine congenital
cohorts frequently perform genotyping only on maternal [219]
or neonatal specimens [230], and those that incorporate both
often present results from unmatched mothers and infants [200].
Even fewer studies compare parasite genotypes between moth-
ers who transmitted to their infants and those who did
not [135]. Due to the small volume of neonatal blood, most
congenital genotyping is reliant on DTU-specific minicircle
probes (TABLE 7) and some studies do not test for all lineages, but
only those predicted to be found circulating locally (conven-
tionally TcI, TcII, TcV and TcVI) [200,169,219]. Cross-reactivity
between minicircle probes for closely related DTUs (TcII and
TcVI) has been reported [168,200], which casts some doubt on
studies detecting co-infections with these lineages [231]. Further-
more, most congenital genotyping studies are constrained by
small sample sizes and suboptimal sensitivity of current
Table 6. Summary of clinical publications which included genotyping to discrete typing unit level in





















































4 Pts (8, 9, 13, 17): blood TcV
Pt10: blood TcV, brain TcII
Pt11: blood TcI + TcV, CSF TcI
Pt12: blood UD, brain TcV














(1), skin (4), and heart
and skin (1)
Blood, heart, skin 4 patients with blood–skin: 2 TcI in
both, 1 TcV in both, 1 TcI in blood,
TcII/VI in skin
1 with blood-heart: TcV in both














Blood: 7 TcI, 1 TcII, 7 TcV, 1 TcII/VI,
4 TcV or V + II/VI, 1 TcVI
Tissue: 4 TcI, 2 TcII, 2 TcV, 2 TcII/VI,











Blood Pt1A (lung): TcV or TcV + TcVI
3 Pts (1B, 2A, 3A; liver): TcV or
TcV + TcVI






Brazil (2002) 1 HIV-T. cruzi
co-infected patient
with CNS reactivation
Blood, CSF Blood: T. cruzi II




Brazil (1999) 28 HIV-T. cruzi
co-infected patients




HIV+: 25 TcII (Clonet 30, 32), 1 TcV
(39), 2 TcVI (43)
HIV: 17 TcII, 1 TcV
Nuclear










Mixed TcI sylvatic/TcIDOM in heart, only





†Unspecified degree of overlap with [104,328,329].
CSF: Cerebral spinal fluid; DTU: Discrete typing unit; MLEE: Multilocus enzyme electrophoresis; RAPD: Random amplification of polymorphic DNA; Pt: Patient;
SL-IR: Spliced-leader intergenic region; UD: Undetectable.
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51 neonates Neonatal cord
or venous
blood
ND TcV (n = 18)
TcII/V/VI (n = 6)
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ND TcV (n = 7)
TcVI (n = 1)
TcII + TcV (n = 1)
TcII + TcVI (n = 1)
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TcI (n = 1)
TcV (n = 12)
TcII (n = 1)
TcV (n = 36)
TcI + TcV/VI













TcII/V/VI refers reactions to markers common to all three DTUs. TcII + TcV + TcVI refers to co-infections determined by markers specific to each DTU.
†Refers to number of clinical samples genotype to DTU level only, not total cohort size.
DTU: Discrete typing unit; kDNA: Kinetoplast DNA; LSSP: Low stringency single specific primer; mHVR: Minicircle hypervariable region; MLEE: Multilocus enzyme electro-
phoresis; ND: Not described; RAPD: Random amplification of polymorphic DNA; RFLP: Restriction fragment length polymorphism; SL-IR: Spliced-leader intergenic region.
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conventional diagnostic methods. Microscopic examination in a
single specimen fails to identify over half of infected neo-
nates [205], and subsequent loss to follow-up is high [212,232,233],
thereby routinely underestimating the rates of congenital
transmission and providing only a fraction of potential parasite
strains for genotyping.
Differential diagnostic sensitivities and rates of follow-up
render it difficult to draw conclusions about geographical
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TcII/V/VI refers reactions to markers common to all three DTUs. TcII + TcV + TcVI refers to co-infections determined by markers specific to each DTU.
†Refers to number of clinical samples genotype to DTU level only, not total cohort size.
DTU: Discrete typing unit; kDNA: Kinetoplast DNA; LSSP: Low stringency single specific primer; mHVR: Minicircle hypervariable region; MLEE: Multilocus enzyme electro-
phoresis; ND: Not described; RAPD: Random amplification of polymorphic DNA; RFLP: Restriction fragment length polymorphism; SL-IR: Spliced-leader intergenic region.










































































variation in congenital transmission. Multiple factors, including
maternal immune response and parasite load, likely modify
risk. Nevertheless, several observations support a contributory
role for parasite genotype in congenital Chagas transmission
risk. In Argentina, women with one congenitally infected child
were significantly more likely to transmit to that child’s siblings
than mothers who had not previously transmitted [234,235]. Con-
sidering the extent of T. cruzi genetic diversity at the intra-
DTU level, it is unlikely that all representatives of a lineage
would be equally permissible to vertical transmission, but it is
conceivable that particular parasite clones may be better
adapted for transplacental infection [235]. Animal data also sup-
port the possibility that some T. cruzi strains are more predis-
posed to vertical transmission than others [236].
To date, only one study has directly examined infected
human placental tissue, detecting additional minicircle signa-
tures not observed in matched maternal blood samples and ten-
tatively supporting the existence of T. cruzi subpopulations
with placental tropism [234]. Others have described parallel dis-
cordant minicircle profiles between paired maternal–neonate
blood specimens, implying either the generation of novel muta-
tions by rapid parasite multiplication during acute neonatal
infection or selective transmission of parasite subpopula-
tions [168]. In the only study to address neonatal morbidity, no
significant association was found between DTU and clinical
severity of congenital infection, but nearly all genotyped speci-
mens in this study were classified as TcV [200].
In one of the aforementioned Argentinean studies, women
from areas with high triatomine infestation had the lowest risk
of congenital transmission compared to those with vector con-
trol (intermediate risk) or from urban areas that had never
been infested (highest risk) [235]. These findings have been con-
firmed in the Bolivian Chaco region, where pregnant women
who had resided longer in an infested house had significantly
lower parasitemia and were less likely to transmit to their child,
compared to those living in areas without vector infestation [237].
Sustained vector exposure and/or repeated re- or super-infection
by T. cruzi may act as an immune booster, allowing women to
maintain effective control of parasitemia, thereby decreasing
their risk of congenital transmission.
Oral T. cruzi transmission and outbreaks of acute
Chagas disease
T. cruzi trypomastigotes in triatomine feces are infectious when
ingested by experimental animals [238], and consumption of
infected vectors or contaminated material is considered the pre-
dominant transmission modality in non-human mammals [6].
Acute T. cruzi infections in humans attributed to oral transmis-
sion have been reported in increasing numbers in recent deca-
des, especially in the Brazilian Amazon [6]. Three basic
scenarios are described: sporadic cases in areas with sylvatic but
not domestic vectors in which the attribution is one of exclu-
sion [6]; small rural family- or village-based clusters of acute
cases traced to shared food or drink [239–242]; and rare large out-
breaks, sometimes in urban areas considered to be free of
vectorial transmission, with an identified common source such
as contaminated fruit or sugarcane juice [243–246]. Most out-
breaks are small, often affecting family groups in the Amazon
region, where the palm fruits ac¸aı´ and bac¸aba are dietary staples
easily contaminated by infected triatomine vectors that live in
the trees themselves [241,247].
The largest reported outbreak, attributed to locally prepared
guava juice, comprised 103 infections among students and staff
at a school in Caracas [244]. Orally transmitted T. cruzi infec-
tion appears to be associated with more severe acute morbidity
and higher mortality than vector-borne infection [239,244,248].
The most frequent symptoms are fever, dyspnea, myalgias, and
generalized and facial edema; ECG changes are also common.
In the Caracas outbreak, 75% of 103 infected individuals were
symptomatic, 66% had ECG abnormalities, 20% were hospi-
talized and there was one death from acute myocarditis [244,248].
Among 13 patients infected in two outbreaks associated with
contaminated sugarcane juice in northeastern Brazil, 92% had
ECG abnormalities, 27% had left ventricular ejection fractions
below 55% and two individuals (age 9 and 16 years) died of
rapidly progressive congestive heart failure [249]. Among survi-
vors, nearly all cardiac abnormalities resolved after treatment
with benznidazole. The higher proportion of symptoms and
severe morbidity and clustering of infections may facilitate eas-
ier detection of acute, oral infection compared to vectorial
cases, and may contribute to the predominance of oral infec-
tions in acute Chagas disease surveillance data [6].
Because of logistical constraints, few outbreaks [241,244] receive
thorough epidemiological investigations, and direct incrimina-
tion of the contaminated item is infrequent. At the DTU level,
T. cruzi genotypes identified in oral outbreaks principally
reflect the predominant lineages circulating in that geographical
area (TABLE 8). In the Caracas school outbreak, molecular typing
demonstrated identical TcI strains in 3 of the 103 infected
individuals and similar strains in a single P. geniculatus cap-
tured at the site where the implicated guava juice was pre-
pared [244,250]. Human specimens from the outbreak in Santa
Catarina in 2005 attributed to sugarcane juice were typed as
TcII [40]. Small family outbreaks in the Amazon region gener-
ally yield TcIV or TcI [95,93,97,99], while rural outbreaks outside
of the Brazilian Amazon (Colombia, Venezuela, French Gui-
ana) detect TcI (sometimes identified specifically as sylvatic
TcI) [240,251–253].
Most investigations occur months after the outbreaks and
consist of vector and animal reservoir studies in the area of the
outbreak [243,95,98,245,254], based on the assumption that outbreak
vehicles were contaminated by infected triatomine feces or anal
gland secretions of infected opossums, which contain infective
trypomastigotes [255]. The investigation in the area of the Santa
Catarina outbreak (typed in humans as TcII) demonstrated TcI
in opossums and both TcI and TcII in triatomine vectors,
implicating local triatomines as the most likely source of
infection [243].
Recent laboratory data suggest that parasite contact with
host gastric acid may render trypomastigotes more invasive
Review Messenger, Miles & Bern












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































through changes in parasite surface glycoproteins, and that this
interaction may underlie the increased clinical severity observed
in orally acquired Chagas disease [256–258]. The T. cruzi surface
glycoprotein gp82 is highly resistant to proteolysis and has
been shown to mediate migration through the stomach mucin
layer and invasion of gastric mucosal cells. Different parasite
strains express distinct isoforms of gp90, a second surface gly-
coprotein, which present differential susceptibility to digestion
by pepsin. Strains with pepsin-digested gp90 have highly effi-
cient gastric mucosal invasion and establish patent T. cruzi
infections, in contrast to those with pepsin-resistant
gp90 which invade poorly. Experimental infection with a
Colombian TcI isolate demonstrated efficient oral and intraper-
itoneal transmission, in contrast to a Peruvian strain (TcV)
which was much less efficient by the oral than the intraperito-
neal route [259]. Similarly, a strain from the 2005 Santa Cata-
rina outbreak (TcII) was highly invasive, producing a robust
infection and high mortality in a mouse model, unlike CL
Brener (TcVI) and G (TcI) strains, with these differences
attributed to the pepsin susceptibility of the gp90 isoforms of
the strains [256].
T. cruzi lineage in Chagas disease diagnostics and
chemotherapy
Diagnosis of Chagas disease in the chronic phase is based on
serological detection of anti-T. cruzi IgG antibodies. However,
no single assay has sufficient sensitivity and specificity to be
used alone; confirmed diagnosis relies on concordant results
from at least two tests using different antigens and/or formats
(usually ELISA, indirect immunofluorescence and/or indirect
hemagglutination) [260]. Differential sensitivities to serodiagnos-
tic tests have been reported between Bolivia and Peru, where
two different commercial rapid tests based on recombinant
antigens demonstrated sensitivities of 87.5 and 90% versus
30 and 54%, respectively [261]. Rapid test sensitivities were
closely correlated with absorbance values on whole parasite
lysate-based ELISAs. Similarly, low sensitivities of recombinant
antigen ELISA and rapid tests have also been reported from
Panama [262,263] and Mexico [264]. No clear correlation between
serodiagnostic test reactivity and local T. cruzi DTU has been
observed; instead, these discrepancies may reflect weaker adap-
tive immune responses to parasite antigens between endemic
populations [265].
Current treatment options for Chagas disease are limited to
benznidazole and nifurtimox. While both drugs have high cure
rates in the acute phase, efficacy during the chronic phase has
been much harder to document, largely due to the lack of a
timely, sensitive test of cure [18,266]. Two recent trials have suc-
cessfully employed quantitative real-time PCR to rapidly detect
treatment failure of the new drug candidates posaconazole and
E1224, a related drug [268–271]. In contrast, fewer than 10% of
those who completed the 60-day benznidazole course had posi-
tive results by PCR during the follow-up period. The posaco-
nazole trial required positive pretreatment results by PCR as a
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by an optimization exercise that achieved 92% sensitivity for
PCR using multiple specimens and optimized techniques.
These two trials provide strong support for the use of PCR as
a primary outcome measure in clinical trials in the chronic
phase. No data on T. cruzi strain are currently available from
these trials, but parasite diversity was unlikely to be high
because the E1224 trial was conducted in Bolivia, and nearly
all patients treated in the posaconazole trial in Spain were also
of Bolivian origins.
Small human studies, clinical impression and findings in ani-
mal models tentatively suggest that parasite susceptibility varies
with geographical location and parasite lineage [272–275] as might
be expected given the crucial role played by some genetic loci
(e.g., TcNTR) in resistance to both benznidazole [276] and nifur-
timox [277]. However, direct human data are sparse and in vitro
epimastigote assays have poor correlation with in vivo mouse
models of drug response [278]. Natural drug resistance to either
drug has been reported in both patient-derived isolates as well
as sylvatic unexposed strains [273,279]. The most comprehensive
in vivo analysis of parasite susceptibility was conducted in the
1980s using 47 parasite strains isolated from patients, sylvatic
reservoirs and vectors, and subsequently inoculated into
mice [273]. In mouse models, cure rates to both benznidazole
and nifurtimox were close to 100% for parasite strains from
Argentina and the southernmost region of Brazil, where the
predominant DTUs are presumed to be TcV and TcVI. In
central and Atlantic Brazil, where TcII is likely to be more
common, cure rates ranged from 50 to 65%, while strains
from sylvatic reservoir hosts and vectors showed highly variable
responses [273].
The inability to dissect the relative contribution of parasite
genetics to treatment failure, disease pathology and progression
represents a major hurdle to the assessment of novel drug
candidates. The advent and optimization of a non-invasive,
in vivo, bioluminescent imaging system which can facilitate
real-time monitoring of chronic parasite burden has the poten-
tial to address these key questions using current and prospective
chemotherapies, prior to human evaluations [280,281].
Expert commentary & five-year view
Establishing or excluding any relationship between T. cruzi
genetic diversity and clinical outcome will require significant
improvements in study design and reporting, patient sampling
and parasite genotyping (BOX 1). As encountered throughout
this article, meta-analyses of historical studies are impeded by
the paucity (and in many cases, complete absence) of descrip-
tive clinical data among genotyping publications. Use of a
standardized CCM stratification method (or supplemental
data to allow reclassification) would facilitate comparison
between studies. Because of the long asymptomatic period
before the onset of clinical signs and symptoms, cross-
sectional evaluations will inevitably misclassify some individu-
als as IND who will later develop CCM; if parasite genetics
contribute to the later progression of disease, this misclassifi-
cation will introduce a bias toward the null hypothesis
(‘parasite genetics are not associated with CCM’). This bias
will be exacerbated if CCM and IND groups are not matched
by age distribution; without deliberate age-matching (individ-
ual or group frequency-matching), the IND group will always
be younger than the symptomatic group due to the natural
history of the disease [25]. Only one genotyping study ensured
that the age distributions of IND and CCM groups were
comparable [189]; no other publications in this review took
this potential confounder into account. Cohort studies of
Chagas cardiomyopathy are rare, but could provide extremely
Box 1. Recommendations to improve assessments
of the interaction between Trypanosoma cruzi
genotype and clinical disease status.
Clinical and epidemiological data
. Use standardized cardiomyopathy stratification scheme and/
or provide supplemental data to allow reclassification
. Present data on specific electrocardiogram and echocardio-
gram abnormalities used to define Chagas cardiomyopathy
. Present data on age; individual or frequency-matching by
age to reduce bias
. Test as representative a sample of cohort or other study par-
ticipants as possible
. Include data collection on other potentially confounding risk
factors such as vector exposure history, immunological
response and human genetics
. Incorporate reliable DTU identification into ongoing and
future cohort studies of cardiomyopathy and congenital Try-
panosoma cruzi transmission
. Develop and validate methods for identification of gastroin-
testinal Chagas disease adaptable to population-based
studies
Data transparency
. Explicit presentation of the relationship between specimens
and patients across publications
. Open-access datasets delinked from personal identifiers, but
maintaining specimen linkage from one study to another
Application of laboratory techniques
. Use of standardized T. cruzi nomenclature, genotyping pro-
tocols, shared reference strains, and central, open-access
repositories of genotypic data
. Genotyping using at least two independent markers to
increase sensitivity, facilitate unequivocal DTU resolution and
mitigate potential misclassification due to parasite
recombination
Improved laboratory techniques
. Techniques for unambiguous DTU classification, particularly
between TcII, TcV and TcVI
. Development of novel methods to enrich parasite DNA suffi-
ciently to enable genotyping directly from low-parasite load
clinical specimens
DTU: Discrete typing unit.










































































valuable opportunities to examine whether T. cruzi strain
affects the risk of development and progression, while avoid-
ing the biases of cross-sectional studies. The strict clinical cri-
teria used in the two most prominent current cohorts (the
control arm of the BENEFIT trial [282] and the REDS-II
study [27]) should provide a firm basis for interpretation,
although thus far, neither has published T. cruzi genotypic
data.
The pathogenesis of Chagas cardiomyopathy is widely
believed to be multifactorial, with contributions from both par-
asite and host genetics; evaluating parasite genotype in isolation
is therefore likely inadequate. The addition of immunology,
human genetics and more detailed epidemiological evaluations
could provide a richer assessment of the possible interactions of
factors modifying clinical outcome. Similarly, studies of con-
genital Chagas disease could be made more rigorous by ensur-
ing that both mother and infant specimens are tested, and that
the source population, criteria for and age at congenital diagno-
sis are more clearly detailed in publications. The maternal
immune response clearly plays an essential role in modulating
congenital transmission risk, and optimally would be evaluated
in tandem with parasite strain diversity [224,225]. Finally, the
impact of vector control initiatives, including changes in force
of infection and circulating strain compositions, needs to be
considered, particularly when comparing genotypic data from
the same endemic area over time.
Epidemiological as well as genotype data are extremely sparse
for GI Chagas disease. The widely accepted observation that
gastrointestinal Chagas disease is much rarer in Central and
northern South America than in the Southern Cone still rests
on clinical reports rather than quantitative population-based
epidemiological studies. In part, this stems from the impracti-
cality of performing barium studies in field conditions and on
large numbers of people. A study in Bolivia used clinical swal-
lowing time (by placing a stethoscope on the neck, asking the
subject to swallow and timing the duration) to assess prevalence
of early esophageal changes; 22% of seropositive participants
had swallowing times longer than the clinically established cut-
off of 10 s, compared to none of the seronegative partici-
pants [283]. If field-friendly methods such as swallowing times
can be validated by comparison with barium studies, this could
provide a useful tool for epidemiological assessments in con-
junction with parasite genetic analysis.
Many articles are difficult to interpret because the relation-
ship between data by specimen and by patient is not explicit.
Synthesis of the literature as a whole is challenging because
multiple manuscripts by the same authors often present geno-
typing data from samples from the same source population,
without specifying the degree of overlap [197,198,284]. Re-
characterization of the same specimens in consecutive papers
may inflate the prevalence estimates of the resulting DTUs. For
all of these limitations, more transparent data presentation
would be invaluable. The current ‘open-access’ movement [193]
may assist in this area, and could be enhanced by the use of
common identifiers between datasets from the same source
population to facilitate such meta-analyses.
Modifications to study design must be complemented by
parallel improvements in clinical T. cruzi genotyping. As previ-
ously discussed, parasite isolation by hemoculture, xenodiagno-
ses or animal inoculation is not ideal and introduces
unquantifiable biases; novel methodologies to enrich T. cruzi
DNA in clinical specimens and circumvent loss of clonal diver-
sity during parasite culturing stages warrant further investiga-
tion. Crucially, the current repertoire of clinical genotyping
techniques is restricted to DTU-level classification and insuffi-
cient to explore the potential interaction between parasite mul-
tiplicity of infection and clinical outcome. Illumina amplicon
sequencing, recently developed to explore intra-host pathogen
genetic diversity, involves the generation of millions of ‘short’
sequencing reads from individual samples, potentially allowing
correlation of read depth with genotype abundance [285–288].
This strategy has been used to examine intra-patient multiclon-
ality among chronic Chagas disease patients, across the clinical
spectrum (asymptomatic to severe cardiomyopathy, megaeso-
phagus or megacolon) in Goia´s, Brazil and matched mother–
infant pairs from Cochabamba, Bolivia. While no relationship
between parasite multiclonality and patient sex, age or clinical
symptoms has been observed thus far, putative evidence of
diversifying selection affecting antigenic genes was detected,
suggesting a link between genetic diversity in this gene family
and survival in the mammalian host [289].
As yet unidentified, diverse genetic characteristics of T. cruzi
may influence clinical outcome. However our systematic
review demonstrates no unequivocal evidence for an associa-
tion between T. cruzi genotype and chronic morbidity, risk of
reactivation, or congenital or oral transmission. In recent pub-
lications, the most consistent finding is that specimens from
all groups reflect the predominant genotypes circulating in the
local area. Results from patients with reactivation indicate that
mixed infections may be the rule, rather than the exception.
Further elucidation of the role of T. cruzi genotype in disease
pathogenesis will require improvements in both study design
and genotyping techniques.
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. Trypanosoma cruzi displays remarkable genetic diversity, which is believed to contribute to the biological, epidemiological and clinical
variation observed among Chagas disease foci.
. T. cruzi strains can be classified into six stable genetic lineages known as discrete typing units (TcI–TcVI), with distributions loosely
defined by geography, ecology and transmission cycle.
. Establishing an association between T. cruzi genotype and clinical outcome is primarily complicated by low peripheral parasitemia in
chronic infections.
. Current evidence suggests that parasite strains detected in patients with or without morbidity reflect the principal lineage circulating
among domestic transmission cycles in that geographical area.
. Likewise, local parasite genotypes are frequently implicated in acute T. cruzi oral outbreaks, which have been increasingly reported in
recent years.
. Loss of immunological control through immunosuppression or HIV co-infection allows sequestered parasites to return to the circulation,
thus providing the best indicator of the complexity of natural infections.
. Women who transmit T. cruzi to one child are more likely to transmit to other offspring, suggesting that parasite genotype may be one
factor influencing the risk of vertical infection. However, to date, the discrete typing units isolated from mothers and infants reflect the
principal lineages circulating in that area.
. Improvements in both study design and genotyping techniques are required to advance our understanding of the role of T. cruzi
genotype in disease pathogenesis.
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